NRG1 Fusions: The New Kid on the Block.

IF 4.7 2区医学 Q1 ONCOLOGY

Current Oncology Reports Pub Date : 2025-02-01 Epub Date: 2025-01-31 DOI:10.1007/s11912-025-01640-y

Brinda Gupta, Leila Borghaei, Stephen V Liu

{"title":"NRG1 Fusions: The New Kid on the Block.","authors":"Brinda Gupta, Leila Borghaei, Stephen V Liu","doi":"10.1007/s11912-025-01640-y","DOIUrl":null,"url":null,"abstract":"Purpose of review: Neuregulin 1 (NRG1) fusions are rare but actionable oncogenic drivers that occur in a variety of tumor types, including non-small cell lung cancer (NSCLC). These fusions lead to pathophysiologic activation of HER signaling pathways, promoting tumor growth, invasion, and metastasis. Current evidence suggests that NRG1 fusion-positive NSCLC does not respond well to conventional treatments such as immunotherapy and chemotherapy. This review focuses on the biology and detection of NRG1 fusions and the evolving therapeutic landscape of NSCLC harboring NRG1 fusions.Recent findings: Zenocutuzumab, a bispecific antibody targeting HER2 and HER3, is the first FDA approved treatment for previously treated NRG1 fusion-positive NSCLC and pancreatic cancer. Additional NRG1 fusion directed strategies are in development. NRG1 fusions are rare molecular drivers of NSCLC that can be effectively treated with targeted therapies. Here, we summarize the biology and detection of NRG1 fusions, the currently approved bispecific antibody used to treat NRG1 fusion-positive NSCLC, and new agents under investigation.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"190-194"},"PeriodicalIF":4.7000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Oncology Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11912-025-01640-y","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/31 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Neuregulin 1 (NRG1) fusions are rare but actionable oncogenic drivers that occur in a variety of tumor types, including non-small cell lung cancer (NSCLC). These fusions lead to pathophysiologic activation of HER signaling pathways, promoting tumor growth, invasion, and metastasis. Current evidence suggests that NRG1 fusion-positive NSCLC does not respond well to conventional treatments such as immunotherapy and chemotherapy. This review focuses on the biology and detection of NRG1 fusions and the evolving therapeutic landscape of NSCLC harboring NRG1 fusions.

Recent findings: Zenocutuzumab, a bispecific antibody targeting HER2 and HER3, is the first FDA approved treatment for previously treated NRG1 fusion-positive NSCLC and pancreatic cancer. Additional NRG1 fusion directed strategies are in development. NRG1 fusions are rare molecular drivers of NSCLC that can be effectively treated with targeted therapies. Here, we summarize the biology and detection of NRG1 fusions, the currently approved bispecific antibody used to treat NRG1 fusion-positive NSCLC, and new agents under investigation.

查看原文本刊更多论文

NRG1 fusion: New Kid on The Block。

综述目的：神经调节蛋白1 （NRG1）融合是一种罕见但可操作的致癌驱动因素，发生在多种肿瘤类型中，包括非小细胞肺癌（NSCLC）。这些融合导致HER信号通路的病理生理激活，促进肿瘤生长、侵袭和转移。目前的证据表明，NRG1融合阳性的NSCLC对免疫治疗和化疗等常规治疗反应不佳。本文综述了NRG1融合体的生物学和检测，以及NRG1融合体的NSCLC治疗前景的发展。Zenocutuzumab是一种靶向HER2和HER3的双特异性抗体，是FDA批准的首个治疗NRG1融合阳性NSCLC和胰腺癌的药物。其他针对NRG1融合的策略正在开发中。NRG1融合是NSCLC的罕见分子驱动因子，可通过靶向治疗有效治疗。在这里，我们总结了NRG1融合体的生物学和检测，目前已批准用于治疗NRG1融合阳性NSCLC的双特异性抗体，以及正在研究的新药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Oncology Reports ONCOLOGY-

CiteScore

8.50

自引率

0.00%

发文量

187

审稿时长

6-12 weeks

期刊介绍： This journal aims to review the most important, recently published clinical findings in the field of oncology. By providing clear, insightful, balanced contributions by international experts, the journal intends to serve all those involved in the care of those affected by cancer. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as cancer prevention, leukemia, melanoma, neuro-oncology, and palliative medicine. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.